SGLT2 HYPE
A project for improving hypertension treatment
Hypertension, a leading cause of heart and kidney diseases, affects over 80 million people in the EU and contributes to one million deaths annually. Despite the availability of treatments, many patients continue to face significant health risks due to inadequate blood pressure control.
SGLT2 inhibitors, a class of drugs commonly used for diabetes and heart failure, have shown potential in lowering blood pressure and providing organ protection due to pleiotropic effects. However, further research is required to confirm their effectiveness in hypertension management
Renown academic and non-academic partners
Envisaged recruiting sites
Countries all over Europe
Clinical Trials.gov Number:
NCT0680416
If you would like to learn more about the study plan and participation criteria click here.
Acronym
SGLT2 HYPE
Project title
SGLT2 inhibition for cardiovascular endpoint reduction in hypertension
Start Date
January 1st 2025
Project Duration
90 months
EU Contribution
€ 6 999 998.95
Grand Agreement Number
101156555
Coordinator
Universitätsklinikum
Schleswig-Holstein (UKSH) – Germany
Principal Investigator
Prof. Ingo Eitel
Coordinating Investigator
Dr. Elias Rawish
Clinical Project Management
Dr. Roza Saraei
The trial
Analysis of protective benefits of Dapaglifozin
The SGLT2 HYPE trial is a large, international study evaluating the effects of dapagliflozin, an SGLT2 inhibitor, in elderly adults with uncontrolled hypertension at cardiovascular risk. This trial will monitor heart and kidney health outcomes in nearly 3,200 participants over a seven-year period, providing critical insights into the potential benefits of SGLT2 inhibitors for hypertension management.
Shaping the Future of Healthcare
Our Vision
To innovate hypertension treatment by introducing a new class of medication that improves heart and kidney health, ultimately reducing preventable illness, disability, and premature deaths on a global scale.
Our Mission
To lead pioneering research that establishes the effectiveness of SGLT2 inhibitors in hypertension management, influencing future treatment guidelines, improving patient outcomes, and driving transformative, life-saving advancements in healthcare.
The SGLT2 HYPE Consortium
Leading Institutions Working Towards Breakthroughs in Healthcare
Our consortium gathers partners from thirteen different countries:
Austria, Czech Republic, France, Germany, Italy, Lithuania, Poland, Portugal, Slovenia, Spain, the United Kingdom, The Netherlands, Ukraine
Find out more here
New EU-funded Project Aims to Transform Hypertension Treatment
SGLT2 HYPE is a guideline-relevant clinical trial aiming to establish SGLT2 inhibitors as a new standard in high blood pressure therapy, ultimately addressing one of the leading causes of premature mortality in Europe